About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Ptger2tm1Brey
targeted mutation 1, Richard M Breyer
MGI:2179967
Summary 10 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
hm1
Ptger2tm1Brey/Ptger2tm1Brey B6.129S6-Ptger2tm1Brey MGI:4834859
hm2
Ptger2tm1Brey/Ptger2tm1Brey C.129S6-Ptger2tm1Brey MGI:4834860
hm3
Ptger2tm1Brey/Ptger2tm1Brey either: (involves: 129S6/SvEvTac) or (involves: 129S6/SvEvTac * C57BL/6) MGI:4834857
hm4
Ptger2tm1Brey/Ptger2tm1Brey involves: 129S6/SvEvTac MGI:4834858
hm5
Ptger2tm1Brey/Ptger2tm1Brey involves: 129S6/SvEvTac * BALB/c MGI:4834863
hm6
Ptger2tm1Brey/Ptger2tm1Brey involves: 129S6/SvEvTac * C57BL/6 MGI:3032591
cx7
Ptger2tm1Brey/Ptger2tm1Brey
Tg(APPswe,PSEN1dE9)85Dbo/0
involves: 129S6/SvEvTac * C3H * C57BL/6 MGI:4834862
cx8
Ptger2tm1Brey/Ptger2tm1Brey
Tg(MMTV-PTGS2)#Thla/0
involves: 129S6/SvEvTac * C57BL/6 * CD-1 * FVB/N MGI:4834864
cx9
Hrhr/Hrhr
Ptger2tm1Brey/Ptger2tm1Brey
involves: 129S6/SvEvTac * C57BL/6 * SKH1 MGI:4834867
cx10
Hrhr/Hrhr
Ptger2tm1Brey/Ptger2+
involves: 129S6/SvEvTac * C57BL/6 * SKH1 MGI:4834868


Genotype
MGI:4834859
hm1
Allelic
Composition
Ptger2tm1Brey/Ptger2tm1Brey
Genetic
Background
B6.129S6-Ptger2tm1Brey
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ptger2tm1Brey mutation (1 available); any Ptger2 mutation (5 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
homeostasis/metabolism
• after middle cerebral artery occlusion induced infarction cerebral blood flow in the non-ischemic contralateral hemisphere is increased compared to wild-type controls (J:87388)
• after middle cerebral artery occlusion induced infarction cerebral blood flow in the non-ischemic contralateral hemisphere is increased compared to wild-type controls (J:87388)
• following 90 min of ischemia induced by middle cerebral artery occlusion and 22.5 h of reperfusion infarct size is significantly larger in mutant males compared to wild-type male controls (J:87388)
• however, no differences in cerebral blood flow in the ischemic hemisphere before, during or after occlusion are detected (J:87388)
• following 90 min of ischemia induced by middle cerebral artery occlusion and 22.5 h of reperfusion infarct size is significantly larger in mutant males compared to wild-type male controls (J:87388)
• however, no differences in cerebral blood flow in the ischemic hemisphere before, during or after occlusion are detected (J:87388)

nervous system
• following 90 min of ischemia induced by middle cerebral artery occlusion and 22.5 h of reperfusion infarct size is significantly larger in mutant males compared to wild-type male controls (J:87388)
• however, no differences in cerebral blood flow in the ischemic hemisphere before, during or after occlusion are detected (J:87388)
• following 90 min of ischemia induced by middle cerebral artery occlusion and 22.5 h of reperfusion infarct size is significantly larger in mutant males compared to wild-type male controls (J:87388)
• however, no differences in cerebral blood flow in the ischemic hemisphere before, during or after occlusion are detected (J:87388)

behavior/neurological
• in a Morris water maze mice show longer escape latencies on each day of testing (J:143076)
• in a Morris water maze mice show longer escape latencies on each day of testing (J:143076)




Genotype
MGI:4834860
hm2
Allelic
Composition
Ptger2tm1Brey/Ptger2tm1Brey
Genetic
Background
C.129S6-Ptger2tm1Brey
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ptger2tm1Brey mutation (1 available); any Ptger2 mutation (5 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
nervous system
• display enhanced phagocytosis of Abeta plaques in an in vitro assay using hippocampal sections from Alzheimer's disease patients (J:97062)
• microglia show enhanced activation and tend to aggregate around Abeta plaques when incubated with hippocampal sections from Alzheimer disease patients (J:97062)
• in culture primary microglial cells show some signs of an activated phenotype but do not display an increase in proliferation (J:97062)
• cultures of mutant microglial cells and wild-type neurons exposed to ABeta1-42 show no signs of the neurotoxicity seen when wild-type microglial cells are used (J:97062)
• display enhanced phagocytosis of Abeta plaques in an in vitro assay using hippocampal sections from Alzheimer's disease patients (J:97062)
• microglia show enhanced activation and tend to aggregate around Abeta plaques when incubated with hippocampal sections from Alzheimer disease patients (J:97062)
• in culture primary microglial cells show some signs of an activated phenotype but do not display an increase in proliferation (J:97062)
• cultures of mutant microglial cells and wild-type neurons exposed to ABeta1-42 show no signs of the neurotoxicity seen when wild-type microglial cells are used (J:97062)
• PGE2 and a PTGER2 agonist fail to induce changes in synaptic activity (J:143076)
• PGE2 and a PTGER2 agonist fail to induce changes in synaptic activity (J:143076)
• in hippocampal slices at 40 and 120 min after theta burst stimulation (J:143076)
• LPS fails to elevate LTP at hippocampal perforant path dentate granule cell synapses (J:143076)
• in hippocampal slices at 40 and 120 min after theta burst stimulation (J:143076)
• LPS fails to elevate LTP at hippocampal perforant path dentate granule cell synapses (J:143076)

immune system
• display enhanced phagocytosis of Abeta plaques in an in vitro assay using hippocampal sections from Alzheimer's disease patients (J:97062)
• microglia show enhanced activation and tend to aggregate around Abeta plaques when incubated with hippocampal sections from Alzheimer disease patients (J:97062)
• in culture primary microglial cells show some signs of an activated phenotype but do not display an increase in proliferation (J:97062)
• cultures of mutant microglial cells and wild-type neurons exposed to ABeta1-42 show no signs of the neurotoxicity seen when wild-type microglial cells are used (J:97062)
• display enhanced phagocytosis of Abeta plaques in an in vitro assay using hippocampal sections from Alzheimer's disease patients (J:97062)
• microglia show enhanced activation and tend to aggregate around Abeta plaques when incubated with hippocampal sections from Alzheimer disease patients (J:97062)
• in culture primary microglial cells show some signs of an activated phenotype but do not display an increase in proliferation (J:97062)
• cultures of mutant microglial cells and wild-type neurons exposed to ABeta1-42 show no signs of the neurotoxicity seen when wild-type microglial cells are used (J:97062)

hematopoietic system
• display enhanced phagocytosis of Abeta plaques in an in vitro assay using hippocampal sections from Alzheimer's disease patients (J:97062)
• microglia show enhanced activation and tend to aggregate around Abeta plaques when incubated with hippocampal sections from Alzheimer disease patients (J:97062)
• in culture primary microglial cells show some signs of an activated phenotype but do not display an increase in proliferation (J:97062)
• cultures of mutant microglial cells and wild-type neurons exposed to ABeta1-42 show no signs of the neurotoxicity seen when wild-type microglial cells are used (J:97062)
• display enhanced phagocytosis of Abeta plaques in an in vitro assay using hippocampal sections from Alzheimer's disease patients (J:97062)
• microglia show enhanced activation and tend to aggregate around Abeta plaques when incubated with hippocampal sections from Alzheimer disease patients (J:97062)
• in culture primary microglial cells show some signs of an activated phenotype but do not display an increase in proliferation (J:97062)
• cultures of mutant microglial cells and wild-type neurons exposed to ABeta1-42 show no signs of the neurotoxicity seen when wild-type microglial cells are used (J:97062)




Genotype
MGI:4834857
hm3
Allelic
Composition
Ptger2tm1Brey/Ptger2tm1Brey
Genetic
Background
either: (involves: 129S6/SvEvTac) or (involves: 129S6/SvEvTac * C57BL/6)
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ptger2tm1Brey mutation (1 available); any Ptger2 mutation (5 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
homeostasis/metabolism
• treatment with PGE2 fails to increase serum calcium levels unlike in wild-type controls (J:77679)
• treatment with PGE2 fails to increase serum calcium levels unlike in wild-type controls (J:77679)




Genotype
MGI:4834858
hm4
Allelic
Composition
Ptger2tm1Brey/Ptger2tm1Brey
Genetic
Background
involves: 129S6/SvEvTac
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ptger2tm1Brey mutation (1 available); any Ptger2 mutation (5 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cardiovascular system
• the renal afferent arteriolar responses to sulprostone and endothelin 1 are increased compared to wild-type controls (J:78902)
• the renal afferent arteriolar responses to sulprostone and endothelin 1 are increased compared to wild-type controls (J:78902)
• norepinephrine precontracted renal afferent arterioles contract rather than dilate in response to PGE2 (1 uM ) or butaprost (1 uM) exposure (J:78902)
• this constriction response can be reversed by angiotensisn converting enzyme inhibition (J:78902)
• norepinephrine precontracted renal afferent arterioles contract rather than dilate in response to PGE2 (1 uM ) or butaprost (1 uM) exposure (J:78902)
• this constriction response can be reversed by angiotensisn converting enzyme inhibition (J:78902)

tumorigenesis
• develop fewer lung tumors following a two stage 3-methylcholanthrene and butylated hydroxytoluene protocol (J:116015)
• develop fewer lung tumors following a two stage 3-methylcholanthrene and butylated hydroxytoluene protocol (J:116015)
• develop smaller lung tumors following a two stage 3-methylcholanthrene and butylated hydroxytoluene protocol (J:116015)
• develop smaller lung tumors following a two stage 3-methylcholanthrene and butylated hydroxytoluene protocol (J:116015)

homeostasis/metabolism
N
• the decrease in tumor burden is not the result of a decrease in butylated hydroxytoluene induced lung inflammation as this response is similar to wild-type controls (J:116015)
• the decrease in tumor burden is not the result of a decrease in butylated hydroxytoluene induced lung inflammation as this response is similar to wild-type controls (J:116015)
• develop fewer lung tumors following a two stage 3-methylcholanthrene and butylated hydroxytoluene protocol (J:116015)
• develop fewer lung tumors following a two stage 3-methylcholanthrene and butylated hydroxytoluene protocol (J:116015)

muscle
• the renal afferent arteriolar responses to sulprostone and endothelin 1 are increased compared to wild-type controls (J:78902)
• the renal afferent arteriolar responses to sulprostone and endothelin 1 are increased compared to wild-type controls (J:78902)
• norepinephrine precontracted renal afferent arterioles contract rather than dilate in response to PGE2 (1 uM ) or butaprost (1 uM) exposure (J:78902)
• this constriction response can be reversed by angiotensisn converting enzyme inhibition (J:78902)
• norepinephrine precontracted renal afferent arterioles contract rather than dilate in response to PGE2 (1 uM ) or butaprost (1 uM) exposure (J:78902)
• this constriction response can be reversed by angiotensisn converting enzyme inhibition (J:78902)




Genotype
MGI:4834863
hm5
Allelic
Composition
Ptger2tm1Brey/Ptger2tm1Brey
Genetic
Background
involves: 129S6/SvEvTac * BALB/c
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ptger2tm1Brey mutation (1 available); any Ptger2 mutation (5 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• LPS induced cerebral oxidative damage is reduced relative to controls (J:164638)
• LPS induced cerebral oxidative damage is reduced relative to controls (J:164638)

nervous system
• LPS induced cerebral oxidative damage is reduced relative to controls (J:164638)
• however, kainic acid induced cerebral oxidative damage is not significantly different from wild-type controls (J:164638)
• LPS induced cerebral oxidative damage is reduced relative to controls (J:164638)
• however, kainic acid induced cerebral oxidative damage is not significantly different from wild-type controls (J:164638)




Genotype
MGI:3032591
hm6
Allelic
Composition
Ptger2tm1Brey/Ptger2tm1Brey
Genetic
Background
involves: 129S6/SvEvTac * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ptger2tm1Brey mutation (1 available); any Ptger2 mutation (5 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
reproductive system
N
• no defects are detected in oocyte maturation or egg fertilization, in vitro (J:69034)
• no defects are detected in implantation or decidualization (J:69034)
• no defects are detected in oocyte maturation or egg fertilization, in vitro (J:69034)
• no defects are detected in implantation or decidualization (J:69034)
• at 2 to 8 months of age females produce far fewer eggs relative to wild-type females (J:69034)
• response to a superovulation protocol is better in young females (3 weeks of age) relative to older females (J:69034)
• at 2 to 8 months of age females produce far fewer eggs relative to wild-type females (J:69034)
• response to a superovulation protocol is better in young females (3 weeks of age) relative to older females (J:69034)
• reduced number of implantations when assessed at E5 (J:53646)
• reduced ovulation and fertilization only about 50% regardless of male genotype (J:53646)
• reduced number of implantations when assessed at E5 (J:53646)
• reduced ovulation and fertilization only about 50% regardless of male genotype (J:53646)
• litter sizes from crosses of homozygous males and females were reduced (J:53646)
• litter sizes from crosses of homozygous males and females were reduced (J:53646)

cardiovascular system
• PGE2-dependent vasodilation effects lost (J:53646)
• PGE2-dependent vasodilation effects lost (J:53646)
• 8-16 week old females with significantly increased systolic pressure (J:53646)
• increased systolic pressure in males as well but not statistically significant (J:53646)
• reversible increase in blood pressure when placed on a high salt diet (J:53646)
• 8-16 week old females with significantly increased systolic pressure (J:53646)
• increased systolic pressure in males as well but not statistically significant (J:53646)
• reversible increase in blood pressure when placed on a high salt diet (J:53646)

respiratory system
• prior treatment with PGE2 fails to reduce the responsiveness to methacholine (J:103373)
• prior treatment with PGE2 fails to reduce the responsiveness to methacholine (J:103373)

immune system
• following infection with Pseudomonas aeruginosa (PA103) bacterial counts in the right lung are lower compared to wild-type controls (J:120725)
• following infection with Pseudomonas aeruginosa (PA103) bacterial counts in the right lung are lower compared to wild-type controls (J:120725)

muscle
• PGE2-dependent vasodilation effects lost (J:53646)
• PGE2-dependent vasodilation effects lost (J:53646)




Genotype
MGI:4834862
cx7
Allelic
Composition
Ptger2tm1Brey/Ptger2tm1Brey
Tg(APPswe,PSEN1dE9)85Dbo/0
Genetic
Background
involves: 129S6/SvEvTac * C3H * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ptger2tm1Brey mutation (1 available); any Ptger2 mutation (5 available)
Tg(APPswe,PSEN1dE9)85Dbo mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
nervous system
• at 12 months of age in males, indices of lipid peroxidation are reduced in the brain suggesting a decrease in oxidative stress relative to transgenic mice wild-type for Ptger2 (J:102728)
• however, no difference is detected at 2 months of age prior to onset of plaque formation (J:102728)
• at 12 months of age in males, indices of lipid peroxidation are reduced in the brain suggesting a decrease in oxidative stress relative to transgenic mice wild-type for Ptger2 (J:102728)
• however, no difference is detected at 2 months of age prior to onset of plaque formation (J:102728)

homeostasis/metabolism
• at 8 and 12 months of age in females and males, respectively, the levels of Abeta peptides and the amyloid plaque load are reduced relative to transgenic mice wild-type for Ptger2 (J:102728)
• at 8 and 12 months of age in females and males, respectively, the levels of Abeta peptides and the amyloid plaque load are reduced relative to transgenic mice wild-type for Ptger2 (J:102728)




Genotype
MGI:4834864
cx8
Allelic
Composition
Ptger2tm1Brey/Ptger2tm1Brey
Tg(MMTV-PTGS2)#Thla/0
Genetic
Background
involves: 129S6/SvEvTac * C57BL/6 * CD-1 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ptger2tm1Brey mutation (1 available); any Ptger2 mutation (5 available)
Tg(MMTV-PTGS2)#Thla mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
reproductive system
N
• unlike transgenic mice wild-type for Ptger2, 12 week old virgin females do not display precocious mammary gland development (J:98801)
• in contrast to transgenic mice wild-type for Ptger2, few multiparous females develop mammary gland hyperplasia (J:98801)
• unlike transgenic mice wild-type for Ptger2, 12 week old virgin females do not display precocious mammary gland development (J:98801)
• in contrast to transgenic mice wild-type for Ptger2, few multiparous females develop mammary gland hyperplasia (J:98801)




Genotype
MGI:4834867
cx9
Allelic
Composition
Hrhr/Hrhr
Ptger2tm1Brey/Ptger2tm1Brey
Genetic
Background
involves: 129S6/SvEvTac * C57BL/6 * SKH1
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Hrhr mutation (17 available); any Hr mutation (30 available)
Ptger2tm1Brey mutation (1 available); any Ptger2 mutation (5 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
tumorigenesis
• UVR induced tumors are more erythematous and have less keratinization (J:117581)
• UVR induced tumors are more likely to be poorly differentiated and deeply invasive compared to tumors in wild-type mice (J:117581)
• UVR induced tumors are more erythematous and have less keratinization (J:117581)
• UVR induced tumors are more likely to be poorly differentiated and deeply invasive compared to tumors in wild-type mice (J:117581)
• while the total number of tumors is reduced, the number of larger lesions (greater than 10 mm in diameter) is increased (J:117581)
• while the total number of tumors is reduced, the number of larger lesions (greater than 10 mm in diameter) is increased (J:117581)
• develop about half as many tumors as wild-type mice following a 15 week escalating light dose protocol (J:117581)
• develop about half as many tumors as wild-type mice following a 15 week escalating light dose protocol (J:117581)

integument
• after a modest UVR exposure (180 mJ/cm2) keratinocyte proliferation is significantly lower compared to wild-type controls (J:117581)
• however, keratinocyte proliferation following higher levels of UVR exposure is similar to wild-type controls (J:117581)
• after a modest UVR exposure (180 mJ/cm2) keratinocyte proliferation is significantly lower compared to wild-type controls (J:117581)
• however, keratinocyte proliferation following higher levels of UVR exposure is similar to wild-type controls (J:117581)




Genotype
MGI:4834868
cx10
Allelic
Composition
Hrhr/Hrhr
Ptger2tm1Brey/Ptger2+
Genetic
Background
involves: 129S6/SvEvTac * C57BL/6 * SKH1
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Hrhr mutation (17 available); any Hr mutation (30 available)
Ptger2tm1Brey mutation (1 available); any Ptger2 mutation (5 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
tumorigenesis
N
• unlike mice homozygous for both alleles, mice heterozygous for Ptger2tm1Brey do not show any protection against tumor formation following a 15 week escalating light dose protocol (J:117581)
• unlike mice homozygous for both alleles, mice heterozygous for Ptger2tm1Brey do not show any protection against tumor formation following a 15 week escalating light dose protocol (J:117581)

integument
• after a modest UVR exposure (180 mJ/cm2) keratinocyte proliferation is significantly lower compared to wild-type controls (J:117581)
• however, keratinocyte proliferation following higher levels of UVR exposure is similar to wild-type controls (J:117581)
• after a modest UVR exposure (180 mJ/cm2) keratinocyte proliferation is significantly lower compared to wild-type controls (J:117581)
• however, keratinocyte proliferation following higher levels of UVR exposure is similar to wild-type controls (J:117581)





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Tumor Biology (MTB), Gene Ontology (GO), MouseCyc
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
01/26/2016
MGI 6.02
The Jackson Laboratory